Prolonged Disease Course of COVID-19 in a Patient with CTLA-4 Haploinsufficiency

Table 1

Immune status investigations when the patient was 22 years old, prior to starting intravenous immunoglobulin substitution therapy.

	Patient’s result	Normal range
IgA (g/L)	0.24	0.70–4.00
IgM (g/L)	<0.30	0.40–2.30
IgG (g/L)	2.74	7.00–16.00
IgG1 (g/L)	2.60	4.90–11.40
IgG2 (g/L)	0.20	1.50–6.40
IgG3 (g/L)	0.50	0.20–1.10
IgG4 (g/L)	0.02	0.08–1.40
Complement AP (%)	115	30–115
Complement CP (%)	128	70–130
Complement MP (%)	145	10–125
Response to pneumococcal polysaccharide vaccination	Severely impaired	Normal
Toxoplasma IgG (IU/mL)	<2	>7.2
Diphtheria antibodies (IU/mL)	0.03	>0.01
Rubella IgG (IU/mL)	11	>10
Tetanus antibodies (IU/mL)	0.38	>0.01

Interpretation of the response to pneumococcal vaccination was based on the 2015 AAAAI/ACAAI criteria. [10]. AP = alternative pathway; CP = classical pathway; MP = lectin pathway.